secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2023-10-23T23:59:59+00:00
Accession:  0000950170-23-054637
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma Settles CaPre Dispute with Aker BioMarine and Doses First Patient in GTX-104 Trial
--------------------------------------------------------------------------------

- Acasti entered a Settlement Agreement with Aker BioMarine to resolve a $2.6 million dispute over a supply agreement for CaPre raw material.
- Under the settlement, Aker BioMarine retains ownership of all raw krill oil, production equipment, and CaPre-related intellectual property.
- Acasti announced dosing of first patient in the pivotal Phase 3 STRIVE-ON safety trial for GTX-104 in aSAH.
- The STRIVE-ON trial aims to support a potential NDA submission anticipated in the first half of calendar 2025.
- Acasti extended its projected cash runway to the first calendar quarter of 2026 following a $7.5 million private placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023054637/0000950170-23-054637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023054637/acst-20231018.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-054637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer